



Formulary Exception/Prior Authorization Request Form

Form with sections: Patient Information, Prescriber Information, Diagnosis and Medical Information. Includes fields for Patient Name, Prescriber Name, Address, City, State, ZIP, Home Phone, Office Phone, Office Fax, Gender, DOB, Medication, Strength, Frequency, Expected Length of Therapy, Qty, Day Supply, Diagnosis, and ICD Code(s).

FORM CANNOT BE EVALUATED WITHOUT REQUIRED CLINICAL INFORMATION

What condition is the drug being prescribed for? _____

Please list all medications the patient has tried specific to the diagnosis and specify below:

Therapeutic failure, including length of therapy for each drug: _____

Drug(s) contraindicated: _____

Adverse event (e.g. toxicity, allergy) for each drug: _____

Is the request for a patient with one or more chronic conditions (e.g., psychiatric condition, diabetes) who is stable on the current drug(s) and who might be at high risk for a significant adverse event with a medication change? Specify anticipated significant adverse event: _____

Does that patient have a chronic condition confirmed by diagnostic testing? If so, please provide diagnostic test and date: _____

Does the patient have a clinical condition for which other alternatives are not recommended based on published guidelines or clinical literature? If so, please provide documentation: _____

Does the patient require a specific dosage form (e.g., suspension, solution, injection)? If so, please provide dosage form: _____

Are additional risk factors (e.g., GI risk, cardiovascular risk, age) present? If so, please provide risk factors: _____

Other: Please provide additional relevant information: _____

REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL DOCUMENTATION TO SUPPORT USE OF THIS MEDICATION.

PLEASE COMPLETE CORRESPONDING SECTION ON PAGE 2 FOR THE SPECIFIC DRUGS/CLASSES LISTED.

FOR ANY DRUG/CLASS NOT LISTED ON PAGE 2, PLEASE ATTACH ADDITIONAL INFORMATION, BUT CANNOT EXCEED TWO PAGES.

PRESCRIPTION BENEFIT PLAN MAY REQUEST ADDITIONAL INFORMATION OR CLARIFICATION, IF NEEDED, TO EVALUATE REQUESTS.

PLEASE FAX COMPLETED FORM TO 1-888-836-0730.

[] Expedited/Urgent Review Requested: By checking this box and signing below, I certify that applying the standard review time frame may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by CVS/caremark®, the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733.

Prescriber Signature: _____ Date: _____

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return fax) and arrange for the return or destruction of these documents.

106-37207A 020416

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

PLEASE COMPLETE CORRESPONDING SECTION FOR THESE SPECIFIC DRUGS/CLASSES LISTED BELOW AND CIRCLE THE APPROPRIATE ANSWER OR SUPPLY RESPONSE.

ANTIFUNGALS:

Does the patient have a diagnosis of Onychomycosis? **Yes or No**. If yes, does the infection involve the toenails, fingernails or both? **(Please circle)**
If the diagnosis is Tinea corporis or Tinea cruris, does the patient require systemic therapy or have more extensive superficial infections? **Yes or No**
If the request is for topical medication, has the patient experienced an inadequate treatment response, intolerance or contraindication to an oral antifungal therapy? **Yes or No**

ANTIEMETIC (5-HT3) AGENTS:

Is the patient receiving moderate to highly emetogenic chemotherapy or receiving radiation therapy? **Yes or No**
If the patient has a diagnosis of Hyperemesis Gravidarum, is the patient a documented risk for hospitalization for rehydration? **Yes or No**
If the patient has a diagnosis of Hyperemesis Gravidarum, has the patient experienced an inadequate treatment response to two of the following medications? **Yes or No**
If yes, please circle two: Vitamin B6, doxylamine, promethazine (Phenergan), trimethobenzamide (Tigan) or metoclopramide (Reglan)

CELEBREX:

Is the patient being treated for post-operative pain following CABG surgery or have active GI bleeding? **Yes or No**
Has the patient received a 30-day supply of an anticoagulant, antiplatelet, an oral corticosteroid or a gastrointestinal medication? **Yes or No**
Has the patient had intolerance to or an inadequate treatment response to a traditional NSAID or NSAID/GI combination product? **Yes or No**
Is the drug being prescribed for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, primary dysmenorrhea or juvenile rheumatoid arthritis? **Please circle all applicable.**

ERECTILE DYSFUNCTION:

Does the patient require nitrate therapy on a regular OR on an intermittent basis? **Yes or No**
Is the drug being prescribed for erectile dysfunction? **Yes or No**
Is the drug being prescribed for Pulmonary Arterial Hypertension (PAH)? **Yes or No**
Is the drug being prescribed for symptomatic Benign Prostatic Hyperplasia (BPH)? **Yes or No**

INSOMNIA AGENTS:

Have other treatable medical/psychological causes of chronic insomnia been considered and/or addressed? **Yes or No**
Have appropriate sleep hygiene and sleep environment issues been addressed? **Yes or No**

PROTON PUMP INHIBITORS:

Does the patient have peptic ulcer disease OR frequent and severe symptoms of GERD (e.g., heartburn, regurgitation) OR atypical symptoms or complications of GERD (e.g., dysphagia, hoarseness, erosive esophagitis)? **Yes or No**
Does the patient have Barrett's esophagus or a Hypersecretory syndrome (e.g. Zollinger-Ellison)? **Yes or No**
Is the patient at high risk for GI adverse events? **Yes or No**

PROVIGIL/NUVIGIL:

Does the patient have a diagnosis of Shift Work Sleep Disorder AND experience excessive sleepiness while working? **Yes or No**
Does the patient have a diagnosis of Obstructive Sleep Apnea, and, if so, is the patient currently using a continuous positive airway pressure (CPAP) machine? **Yes or No**
Does the patient have a diagnosis of Narcolepsy? **Yes or No**
If the patient has a diagnosis of Narcolepsy, has the diagnosis been confirmed by sleep lab evaluation? **Yes or No**

STIMULANTS: AMPHETAMINES, METHYLPHENIDATES, STRATTERA

Does the patient have a diagnosis of ADHD or ADD? **Yes or No**
Has the diagnosis been documented (i.e., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires)? **Yes or No**
Does the patient have a diagnosis of Narcolepsy? **Yes or No**
If the patient has a diagnosis of Narcolepsy, has the diagnosis been confirmed by sleep lab evaluation? **Yes or No**

TRETINOIN PRODUCTS:

Does the patient have the diagnosis of acne vulgaris or keratosis folliculus? **Yes or No**

TAZORAC:

Does the patient have a diagnosis of acne or plaque psoriasis? **Yes or No**
If the patient is female, has the physician discussed with the patient the potential risks of fetal harm and importance of birth control while using Tazorac? **Yes or No**
Will the patient be applying Tazorac to less than 20 percent of body surface area? **Yes or No**

TESTOSTERONE PRODUCTS:

Before start of testosterone therapy did the patient (or does the patient currently) have two confirmed low testosterone levels or absence of endogenous testosterone? **Yes or No**
Does the patient have carcinoma of the breast or known or suspected prostate cancer? **Yes or No**

TRIPTANS:

Does the patient have confirmed or suspected cardiovascular or cerebrovascular disease, or uncontrolled hypertension? **Yes or No**
Does the patient have a diagnosis of migraine headache or cluster headache? **Yes or No**
Is the patient currently using migraine prophylactic therapy (e.g., amitriptyline, propranolol, timolol)? **Yes or No**
Has medication overuse headache been considered and ruled out? **Yes or No**